Product Description
A monoclonal antibody targeting an as of yet undisclosed tumor-associated antigen (TAA), with potential antineoplastic activity. Upon administration of B013, the monoclonal antibody targets and binds to the TAA expressed on tumor cells. This may result in the death of tumor cells expressing the TAA through an as of yet not elucidated mechanism of action. (Sourced from: https://www.cancer.gov/publications/dictionaries/cancer-drug/def/monoclonal-antibody-b013)
Mechanisms of Action: Unknown
Novel Mechanism: No
Modality: Antibody
Route of Administration: Intravenous
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Shanghai Jiaolian Drug Research and Development Co., Ltd
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: China
Active Clinical Trial Count: 2
Highest Development Phases
Phase 3: Triple Negative Breast Cancer
Phase 2: Ovarian Cancer
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| SPH-B013-201 | P2 |
Recruiting |
Ovarian Cancer |
2026-12-31 |
|
| B013-301 | P3 |
Recruiting |
Triple Negative Breast Cancer |
2024-12-01 |